TipRanks
Advertisement
Advertisement

OKYO Stock Latest News

OKYO Pharma to Showcase Urcosimod at Key European Ophthalmology Forums
Company AnnouncementsOKYO Pharma to Showcase Urcosimod at Key European Ophthalmology Forums
10d ago
6K
OKYO
OKYO Pharma to Highlight Urcosimod Progress at Cantor Global Healthcare Conference
PremiumCompany Announcements
OKYO Pharma to Highlight Urcosimod Progress at Cantor Global Healthcare Conference
11d ago
6K
OKYO
Okyo Pharma management to meet virtually with Piper Sandler
PremiumThe Fly
Okyo Pharma management to meet virtually with Piper Sandler
26d ago
OKYO
OKYO Pharma CSO Increases Stake Ahead of Planned Phase 3 Trial
PremiumCompany Announcements
OKYO Pharma CSO Increases Stake Ahead of Planned Phase 3 Trial
2M ago
6K
OKYO
Okyo Pharma CSO Raj Patil purchases 3,363 shares at $1.49
PremiumThe Fly
Okyo Pharma CSO Raj Patil purchases 3,363 shares at $1.49
2M ago
OKYO
OKYO Pharma to Present Late-Stage Ophthalmic Pipeline at BTIG Biotechnology Conference 2026
PremiumCompany AnnouncementsOKYO Pharma to Present Late-Stage Ophthalmic Pipeline at BTIG Biotechnology Conference 2026
2M ago
6K
OKYO
OKYO Pharma Director Ups Stake Ahead of Planned Phase 3 Neuropathic Corneal Pain Trial
Premium
Company Announcements
OKYO Pharma Director Ups Stake Ahead of Planned Phase 3 Neuropathic Corneal Pain Trial
2M ago
6K
OKYO
Okyo Pharma director John Brancaccio acquires 5,000 shares at $1.38
Premium
The Fly
Okyo Pharma director John Brancaccio acquires 5,000 shares at $1.38
2M ago
OKYO
Okyo Pharma CEO Robert Dempsey purchases 15,000 shares at $1.54
PremiumThe Fly
Okyo Pharma CEO Robert Dempsey purchases 15,000 shares at $1.54
2M ago
OKYO
OKYO Pharma CEO Boosts Stake With Nasdaq Share Purchase
PremiumCompany Announcements
OKYO Pharma CEO Boosts Stake With Nasdaq Share Purchase
2M ago
6K
OKYO
OKYO Pharma Chairman Boosts Stake to Over 20% Ahead of Phase 3 Trial
PremiumCompany Announcements
OKYO Pharma Chairman Boosts Stake to Over 20% Ahead of Phase 3 Trial
2M ago
6K
OKYO
Okyo Pharma says Chairman Gabriele Cerrone buys 22,500 shares at $1.45/share
PremiumThe Fly
Okyo Pharma says Chairman Gabriele Cerrone buys 22,500 shares at $1.45/share
2M ago
OKYO
OKYO Pharma Executive Boosts Shareholding Ahead of Planned Phase 3 NCP Trial
PremiumCompany AnnouncementsOKYO Pharma Executive Boosts Shareholding Ahead of Planned Phase 3 NCP Trial
2M ago
6K
OKYO
Okyo Pharma says CDO Gary Jacob purchases 3,500 shares for $1.40 per share
Premium
The Fly
Okyo Pharma says CDO Gary Jacob purchases 3,500 shares for $1.40 per share
2M ago
OKYO
Okyo Pharma CMO Flavio Mantelli purchases 20,000 shares at $1.40
Premium
The Fly
Okyo Pharma CMO Flavio Mantelli purchases 20,000 shares at $1.40
2M ago
OKYO
OKYO Pharma CMO Boosts Stake Ahead of Planned Global Phase 3 Trial
PremiumCompany Announcements
OKYO Pharma CMO Boosts Stake Ahead of Planned Global Phase 3 Trial
2M ago
6K
OKYO
OKYO Pharma to Present Ophthalmology Pipeline Ahead of Phase 3 Urcosimod Trial
PremiumCompany Announcements
OKYO Pharma to Present Ophthalmology Pipeline Ahead of Phase 3 Urcosimod Trial
2M ago
6K
OKYO
OKYO Pharma Chairman Boosts Stake Ahead of Phase 3 Neuropathic Corneal Pain Trial
PremiumCompany Announcements
OKYO Pharma Chairman Boosts Stake Ahead of Phase 3 Neuropathic Corneal Pain Trial
2M ago
6K
OKYO
Okyo Pharma chairman Gabriele Cerrone buys 25,000 shares at $1.40 per share
PremiumThe Fly
Okyo Pharma chairman Gabriele Cerrone buys 25,000 shares at $1.40 per share
2M ago
OKYO
OKYO Pharma Files Annual Report and Secures Funding for Phase 3 NEPTUNE Trial
PremiumCompany AnnouncementsOKYO Pharma Files Annual Report and Secures Funding for Phase 3 NEPTUNE Trial
2M ago
6K
OKYO
Okyo Pharma price target lowered to $5 from $7 at H.C. Wainwright
Premium
The Fly
Okyo Pharma price target lowered to $5 from $7 at H.C. Wainwright
2M ago
OKYO
Okyo Pharma receives feedback from FDA Type D meeting on urcosimod pathway
Premium
The Fly
Okyo Pharma receives feedback from FDA Type D meeting on urcosimod pathway
2M ago
OKYO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >